Has your household member been diagnosed with COVID-19 in the past 4 days?
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2
This study enrolls adults who have a household member diagnosed with COVID-19 in the past 96 hours but who do not have symptoms themselves. The purpose of this study is to find out if an investigational drug is safe and effective at preventing or reducing symptoms and COVID infection
You will have a one-time injection with either the study drug or a placebo. You will have tests done several times, like having nose and saliva samples taken, urine samples, and having blood drawn. Some follow up visits can be done in your home over the course of 8 months.
-To evaluate the efficacy of REGN10933+REGN10987 compared to placebo inpreventing symptomatic SARS-CoV-2 infection (strict-term) confirmed by RT-qPCR-To evaluate the efficacy of REGN10933+REGN10987 compared to placebo inpreventing asymptomatic or symptomatic SARS-CoV-2 infection confirmed byRT-qPCR Site For COV-2069 Household
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Adults ages 18+.
Do not have symptoms of COVID-19
Have a household member who has been diagnosed with COVID-19 in the past 96 hours.
Due to COVID-19, new enrollment in research studies will be greatly limited.
If you are interested in a study, there may be a longer waiting period to receive a response to your inquiry.
View the guidance for research participants for additional information.
Let us know how the study team can reach you.
If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email firstname.lastname@example.org and someone will assist you.